NAPROXEN- naproxen tablet, delayed release

Pays: États-Unis

Langue: anglais

Source: NLM (National Library of Medicine)

Ingrédients actifs:

NAPROXEN (UNII: 57Y76R9ATQ) (NAPROXEN - UNII:57Y76R9ATQ)

Disponible depuis:

REMEDYREPACK INC.

DCI (Dénomination commune internationale):

NAPROXEN

Composition:

NAPROXEN 375 mg

Mode d'administration:

ORAL

Type d'ordonnance:

PRESCRIPTION DRUG

indications thérapeutiques:

Naproxen delayed-release tablets are indicated for: The relief of the signs and symptoms of: - rheumatoid arthritis - osteoarthritis - ankylosing spondylitis - Polyarticular Juvenile Idiopathic Arthritis Naproxen delayed-release tablets are contraindicated in the following patients: - Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product [ see Warnings and Precautions ( 5.7, 5.9)] - History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [ see Warnings and Precautions ( 5.7, 5.8)] - In the setting of coronary artery bypass graft (CABG) surgery [ see Warnings and Precautions ( 5.1)] Risk Summary Use of NSAIDs, including naproxen delayed-release tablets, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including napr

Descriptif du produit:

Naproxen Delayed-Release Tablets USP are supplied as follows: 375 mg: White to off-white, capsule-shaped, enteric-coated, unscored tablets imprinted on one side in blue ink with 93-5. They are available in bottles of 100 (NDC 0093-1005-01) and 500 tablets (NDC 0093-1005-05). 500 mg: White to off-white, capsule-shaped, enteric-coated, unscored tablets imprinted on one side in blue ink with 93-6. They are available in bottles of 100 (NDC 0093-1006-01) and 500 (NDC 0093-1006-05) tablets. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Statut de autorisation:

Abbreviated New Drug Application

Notice patient

REMEDYREPACK INC.
----------
Medication Guide for Nonsteroidal Anti-
inflammatory Drugs (NSAIDs)
What is the most important information I
should know about medicines called
Nonsteroidal Anti-inflammatory Drugs
(NSAIDs)?
NSAIDs can cause serious side effects,
including:
•
Increased risk of a heart attack or
stroke that can lead to death. This
risk may happen early in
treatment and may increase:
•
with increasing doses of NSAIDs
•
with longer use of NSAIDs
Do not take NSAIDs right before or after
a heart surgery called a “coronary artery
bypass graft (CABG).” Avoid taking
NSAIDs after a recent heart attack, unless
your healthcare provider tells you to. You
may have an increased risk of another
heart attack if you take NSAIDs after a
recent heart attack.
•
Increased risk of bleeding, ulcers,
and tears (perforation) of the
esophagus (tube leading from the
mouth to the stomach), stomach
and intestines:
•
anytime during use
•
without warning symptoms
•
that may cause death
The risk of getting an ulcer or bleeding
increases with:
•
past history of stomach ulcers, or
stomach or intestinal bleeding
with use of NSAIDs
•
taking medicines called
“corticosteroids”,
“anticoagulants”, “SSRIs”, or
“SNRIs”
•
increasing
doses of
NSAIDs
•
older age
•
longer use of
NSAIDs
•
poor
health
•
smoking
•
advanced
liver
disease
•
drinking
alcohol
•
bleeding
problems
NSAIDs should only be used:
•
exactly as prescribed
•
at the lowest dose possible for
your treatment
•
for the shortest time needed
What are NSAIDs?
NSAIDs are used to treat pain and
redness, swelling, and heat
(inflammation) from medical conditions
such as different types of arthritis,
menstrual cramps, and other types of
short-term pain.
Who should not take NSAIDs?
Do not take NSAIDs:
•
if you have had an asthma attack,
hives, or other allergic reaction
with aspirin or any other NSAIDs.
•
right before or after heart bypass
surgery.
Before taking NSAIDs, tell your
healthcare provider about all of your
medical condi

Résumé des caractéristiques du produit

NAPROXEN- NAPROXEN TABLET, DELAYED RELEASE
REMEDYREPACK INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
NAPROXEN DELAYED-RELEASE TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR NAPROXEN
DELAYED-RELEASE TABLETS.
NAPROXEN DELAYED-RELEASE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1976
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) CAUSE AN INCREASED RISK
OF SERIOUS CARDIOVASCULAR
THROMBOTIC EVENTS, INCLUDING MYOCARDIAL INFARCTION AND STROKE, WHICH
CAN BE FATAL. THIS RISK MAY OCCUR
EARLY IN TREATMENT AND MAY INCREASE WITH DURATION OF USE. ( 5.1)
NAPROXEN DELAYED-RELEASE TABLETS ARE CONTRAINDICATED IN THE SETTING OF
CORONARY ARTERY BYPASS GRAFT
(CABG) SURGERY. ( 4, 5.1)
NSAIDS CAUSE AN INCREASED RISK OF SERIOUS GASTROINTESTINAL (GI)
ADVERSE EVENTS INCLUDING BLEEDING,
ULCERATION, AND PERFORATION OF THE STOMACH OR INTESTINES, WHICH CAN BE
FATAL. THESE EVENTS CAN OCCUR AT
ANY TIME DURING USE AND WITHOUT WARNING SYMPTOMS. ELDERLY PATIENTS AND
PATIENTS WITH A PRIOR HISTORY
OF PEPTIC ULCER DISEASE AND/OR GI BLEEDING ARE AT GREATER RISK FOR
SERIOUS GI EVENTS. ( 5.2)
RECENT MAJOR CHANGES
Boxed Warning 05/2016
Warnings and Precautions ( 5.1, 5.5) 05/2016
INDICATIONS AND USAGE
Naproxen delayed-release tablets are non-steroidal anti-inflammatory
drugs indicated for: (1)
the relief of the signs and symptoms of: (1)
rheumatoid arthritis
os te oarthritis
ankylosing spondylitis
polyarticular juvenile idiopathic arthritis
DOSAGE AND ADMINISTRATION
Use the lowest effective dosage for shortest duration consistent with
individual patient treatment goals. (2.1) (2)
Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis (2)
Naproxen Delayed-Release Tablets (2)
375 mg or 500 mg (2)
twice daily (2)
To maintain the integrity of the enteric coating, the naproxen
delayed-release tablet should not be broken, crus